EDP1503

BIOLOGICAL2 trials

Sponsors

University of Chicago, Evelo Biosciences, Inc.

Conditions

Bladder CancerColorectal Cancer MetastaticGastroEsophageal CancerMSI-HMelanomaMelanoma (Skin)Non Small Cell Lung CancerRenal Cell Carcinoma

Phase 1

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

CompletedNCT03775850

Evelo Biosciences, Inc.Bladder Cancer, Colorectal Cancer Metastatic, GastroEsophageal Cancer +4

Start: 2018-12-19End: 2021-10-31Updated: 2023-03-24

Phase 2

Pembrolizumab and EDP1503 in Advanced Melanoma

TerminatedNCT03595683

University of ChicagoMelanoma, Melanoma (Skin)

Start: 2018-10-02End: 2025-07-31Updated: 2025-12-08

Related Papers

Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors

Investigational New Drugs2025-08-014 citations

Abstract PS11-27: A phase I/II clinical trial of EDP1503 with pembrolizumab for triple-negative breast cancer

Cancer Research2021-02-155 citations

Monoclonal microbial EDP1503 to induce antitumor responses via gut-mediated activation of both innate and adaptive immunity.

Journal of Clinical Oncology2019-05-208 citations